Respiratory tract allergic disease and atopy: Experimental evidence for a fungal infectious etiology

Medical Mycology

Volumn 49, Issue SUPPL. 1, 2011, Pages

  Porter, Paul ^a   Polikepahad, Sumanth ^a   Qian, Yuping ^a   Morgan Knight, J ^a   Lu, Wen ^a   Tai, Wendy M T ^a   Roberts, Luz ^a   Ongeri, Valentine ^a   Yang, Tianshu ^a   Seryshev, Alexander ^a   Abramson, Stuart ^a   Delclos, George L ^a   Kheradmand, Farrah ^a   Corry, David B ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

asthma; atopy; fungus

Indexed keywords

FUNGUS ANTIGEN; HOUSE DUST ALLERGEN; OVALBUMIN; POLLEN ANTIGEN; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 2;

ALLERGENICITY; ALLERGIC ASTHMA; ASPERGILLUS FUMIGATUS; ASPERGILLUS NIGER; ATOPY; CONFERENCE PAPER; CONIDIUM; DERMATOPHAGOIDES; DISEASE MODEL; ENZYME ACTIVITY; HUMAN; LUNG ASPERGILLOSIS; MYCOSIS; NONHUMAN; PROTEIN FUNCTION; RAGWEED; RESPIRATORY TRACT INFECTION; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; ASTHMA; DISEASE MODELS, ANIMAL; FUNGAL PROTEINS; FUNGI; INTERLEUKIN-13; INTERLEUKIN-4; LUNG; MICE; MYCOSES; PEPTIDE HYDROLASES; RESPIRATORY SYSTEM; TH2 CELLS;

FUNGI; MUS;

EID: 79952657386     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.509743     Document Type: Conference Paper

References (51)

1. Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002; 109: S482-S489. (Pubitemid 34499500)
2. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107: 3-8. (Pubitemid 32105235)
3. Peat JK, Salome CM, Woolcock AJ. Factors associated with bronchial hyperresponsiveness in Australian adults and children. Eur Respir J 1992; 5: 921-929.
4. Ishizaka T, Ishizaka K, Tomioka H. Release of histamine and slow reacting substance of anaphylaxis (SRS-A) by IgE-anti-IgE reactions on monkey mast cells. J Immunol 1972; 108: 513-520.
5. Turnbull LS, Turnbull LW, Leitch AG, Crofton JW, Kay AB. Mediators of immediate-type hypersensitivity in sputum from patients with chronic bronchitis and asthma. Lance t 1977; 2: 526-529. (Pubitemid 8186303)
6. Corry DB, Grunig G, Hadeiba H, et al. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol Med 1998; 4: 344-355. (Pubitemid 28361658)
7. Mehlhop PD, van de Rijn M, Goldberg AB, et al. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA 1997; 94: 1344-1349. (Pubitemid 27087853)
8. Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183: 109-117. (Pubitemid 26028750)
9. Takeda K, Hamelmann E, Joetham A, et al. Development of eosi-nophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997; 186: 449-454. (Pubitemid 27332903)
10. Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988; 334: 255-258.
11. Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-2263. (Pubitemid 29004075)
12. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258-2261. (Pubitemid 29004074)
13. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 2005; 202: 829-839. (Pubitemid 41345971)
14. Angkasekwinai P, Park H, Wang Y-H, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 2007; 204: 1509-1517. (Pubitemid 47048018)
15. Corry DB, Irvin CG. Promise and pitfalls in animal-based asthma research: Building a better mousetrap. Immunol Res 2006; 35: 279-294. (Pubitemid 46020728)
16. Zhang Y, Lamm WJ, Albert RK, et al. Influence of the route of allergen administration and genetic background on the murine allergic pulmonary response. Am J Respir Crit Care Med 1997; 155: 661-669. (Pubitemid 27085817)
17. Wills-Karp M, Ewart SL. The genetics of allergen-induced airway hyperresponsiveness in mice. Am J Respir Crit Care Med 1997; 156: S89-596.
18. Yiamouyiannis CA, Schramm CM, Puddington L, et al. Shifts in lung lymphocyte prof les correlate with the sequential development of acute allergic and chronic tolerant stages in a murine asthma model. Am J Path 1999; 154: 1911-1921. (Pubitemid 29262875)
19. Donnelly S, Dalton JP, Loukas A. Proteases in Helminth- and Allergen-induced inflammatory Responses. Basel: Karger; 2006.
20. Gough L, Sewell HF, Shakib F. The proteolytic activity of the major dust mite allergen Der p 1 enhances the IgE antibody response to a bystander antigen. Clin Exp Allergy 2001; 31: 1594-1598. (Pubitemid 32939467)
21. Ghaemmaghami AM, Robins A, Gough L, Sewell HF, Shakib F. Human T cell subset commitment determined by the intrinsic property of antigen: the proteolytic activity of the major mite allergen Der p 1 conditions T cells to produce more IL-4 and less IFN-gamma. Eur J Immunol 2001; 31: 1211-1216.
22. Shakib F, Gough L. The proteolytic activity of Der p 1 selectively enhances IgE synthesis: a link between allergenicity and cysteine protease activity. Clin Exp Allergy 2000; 30: 751-752. (Pubitemid 30341277)
23. Wan H, Winton HL, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. J Clin Invest 1999; 104: 123-133. (Pubitemid 29534352)
24. Gough L, Schulz O, Sewell HF, Shakib F. The cysteine protease activity of the major dust mite allergen Der p 1 selectively enhances the immunoglobulin E antibody response. J Exp Med 1999; 190: 1897-902.
25. Shakib F, Schulz O, Sewell H. A mite subversive: cleavage of cD23 and CD25 by Der p 1 enhances allergenicity. Immunol Today 1998; 19: 313-316. (Pubitemid 28322327)
26. Schulz O, Sewell HF, Shakib F. Proteolytic cleavage of cD25, the alpha subunit of the human T cell interleukin 2 receptor, by Der p 1, a major mite allergen with cysteine protease activity. J Exp Med 1998; 187: 271-275. (Pubitemid 28060444)
27. King C, Brennan S, Thompson PJ, Stewart GA. Dust mite proteolytic allergens induce cytokine release from cultured airway epithelium. J Immunol 1998; 161: 3645-3651.
28. Comoy EE, Pestel J, Duez C, et al. The house dust mite allergen, Der-matophagoides pteronyssinus, promotes type 2 responses by modulating the balance between IL-4 and IFN-gamma. J Immunol 1998; 160: 2456-2462. (Pubitemid 28119931)
29. Kheradmand F, Kiss A, Xu J, et al. A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease. J Immunol 2002; 169: 5904-5911. (Pubitemid 35291696)
30. Porter P, Susarla SC, Polikepahad S, et al. Link between allergic asthma and airway mucosal infection suggested by proteinase-secreting household fungi. Mucosal Immunol 2009; 2: 504-517.
31. Sporik R, Holgate ST, Platts-Mills TA, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. A prospective study. N Engl J Med 1990; 323: 502-507. (Pubitemid 20260050)
32. Xavier MO, Sales MdPU, Camargo JdJP, Pasqualotto AC, Severo LC. Aspergillus niger causing tracheobronchitis and invasive pulmonary aspergillosis in a lung transplant recipient: case report. Rev Soc Bras Med Trop 2008; 41: 200-201. (Pubitemid 351872403)
33. Luce JM, Ostenson RC, Springmeyer SC, Hudson LD. Invasive asper-gillosis presenting as pericarditis and cardiac tamponade. Chest 1979; 76: 703-705. (Pubitemid 10207740)
34. Gioulekas D, Damialis A, Papakosta D, et al. Allergenic fungi spore records (15 years) and sensitization in patients with respiratory allergy in Thessaloniki-Greece. J Investig Allergol Clin Immunol 2004; 14: 225-231. (Pubitemid 39390279)
35. Ezeamuzie CI, Al-Ali S, Khan M, et al. IgE-mediated sensitization to mould allergens among patients with allergic respiratory diseases in a desert environment. Int Arch Allergy Immunol 2000; 121: 300-307. (Pubitemid 30229642)
36. Wills-Karp M. Immunologic basis of antigen-induced airway hyper-responsiveness. Annu Rev Immunol 1999; 17: 255-281. (Pubitemid 29241125)
37. Gudmundsson G, Hunninghake GW. Interferon-gamma is necessary for the expression of hypersensitivity pneumonitis. J Clin Invest 1997; 99: 2386-2390. (Pubitemid 27227715)
38. Mattern IE, van Noort JM, van den Berg P, et al. Isolation and characterization of mutants of Aspergillus niger deficient in extracellular proteases. Mol Gen Genet 1992; 234: 332-336.
39. Kiss A, Montes M, Susarla S, et al. A new mechanism regulating the initiation of allergic airway inflammation. J Allergy Clin Immunol 2007; 120: 334-342. (Pubitemid 47102383)
40. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999; 11: 13-18. (Pubitemid 29082330)
41. Schnare M, Barton GM, Holt AC, et al. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001; 2: 947-950. (Pubitemid 32976167)
42. Medzhitov R, Preston-Hurlburt P, Kopp E, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258. (Pubitemid 128373651)
43. Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009; 457: 585-588.
44. Humbles AA, Lu B, Nilsson CA, et al. A role for the C3a anaphy-latoxin receptor in the effector phase of asthma. Nature 2000; 406: 998-1001.
45. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA. Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J Immunol 2002; 169: 5926-5933. (Pubitemid 35291699)
46. Schmidlin F, Amadesi S, Dabbagh K, et al. Protease-activated receptor 2 mediates eosinophil inf ltration and hyperreactivity in allergic inflammation of the airway. J Immunol 2002; 169: 5315-5321. (Pubitemid 35217205)
47. Ebeling C, Forsythe P, Ng J, et al. Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. J Allergy Clin Immuno l 2005; 115: 623-630. (Pubitemid 40341720)
48. D'Agostino B, Roviezzo F, De Palma R, et al. Activation of protease-activated receptor-2 reduces airways inflammation in experimental allergic asthma. Clin Experimen Allergy 2007; 37: 1436-1443. (Pubitemid 47460224)
49. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensi-tization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-18.
50. Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itra-conazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756-762. (Pubitemid 30151919)
51. Ward GW, Jr., Woodfolk JA, Hayden ML, Jackson S, Platts-Mills TA. Treatment of late-onset asthma with fluconazole. J Allergy Clin Immunol 1999; 104: 541-546. (Pubitemid 29451641)